Anzeige
Mehr »
Donnerstag, 17.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1T7BJ | ISIN: US29251M1062 | Ticker-Symbol: 9EP
Tradegate
15.07.25 | 15:34
6,100 Euro
0,00 % 0,000
1-Jahres-Chart
ENANTA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ENANTA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,0006,25014:11
6,0006,25014:11

Aktuelle News zur ENANTA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.06.AbbVie wins FDA nod for a label expansion of Enanta-partnered antiviral5
05.06.Enanta Pharmaceuticals bei Jefferies: Strategischer Fokus auf RSV und Immunologie2
03.06.Citizens JMP raises Enanta Pharmaceuticals stock price target to $2410
22.05.Enanta to present RSV drug study results at ESPID 20259
22.05.Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting347Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that...
► Artikel lesen
ENANTA Aktie jetzt für 0€ handeln
14.05.ENANTA PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans1
14.05.Enanta stock price target raised to $23 by JMP4
08.04.Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025352Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that data from...
► Artikel lesen
17.03.ENANTA PHARMACEUTICALS INC - 8-K, Current Report2
12.02.ENANTA PHARMACEUTICALS INC - 10-Q, Quarterly Report1
11.02.The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts2
11.02.JMP Securities maintains Enanta stock with $21 target3
10.02.Enanta Pharma GAAP EPS of -$1.05 beats by $0.32, revenue of $16.96M misses by $0.29M3
10.02.Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024125WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...
► Artikel lesen
10.02.ENANTA PHARMACEUTICALS INC - 8-K, Current Report-
24.12.24Enanta Plans To Appeal Court Ruling Related To 953 Patent Infringement Lawsuit577NEW YORK CITY (dpa-AFX) - Enanta Pharmaceuticals (ENTA) announced the United States District Court of Massachusetts has issued a ruling on a summary judgment motion filed by Pfizer, in connection...
► Artikel lesen
25.11.24Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024168WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...
► Artikel lesen
05.08.24Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter175WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1